Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes prior to informed consent~* Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:~  * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,~ * pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). Individual antidiabetic drug will have to be discontinued at Visit 1.~* haemoglobin A1c (HbA1c) at Visit 1 (screening)~  * for patients without antidiabetic therapy : HbA1c \>=8.0 to =\<10.5%~ * for patients with one oral antidiabetic drug : HbA1c \>=7.5 to =\<10.5%~* HbA1c \>=7.5 to =\<10.0% at Visit 4 for randomisation into the double blind treatment period~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>270 mg/dL (\>15.0 mmol/L) during the open label stabilisation period and placebo run in period~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empagliflozin 10 mg + linagliptin 5 mg (Type: EXPERIMENTAL): patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
- empagliflozin 10 mg (Type: EXPERIMENTAL): patient to receive a tablet containing low dose empagliflozin once daily
- empagliflozin 25 mg + linagliptin 5 mg (Type: EXPERIMENTAL): patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
- empagliflozin 25 mg (Type: EXPERIMENTAL): patients to receive a tablet containing high dose empagliflozin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).